Columbia University is initiating a clinical trial to evaluate whether the herbal supplement Zyflamend inhibits the onset of prostate cancer in certain patients. New Chapter, the Brattleboro, VT-based firm that manufactures the supplement, is providing funding for the Phase I study. The trial is the first clinical examination of its kind for an herbal prostate cancer prevention treatment, according to a Columbia University press release. Zyflamend is composed of 10 herbs purported to work along the COX-2 pathway: rosemary; turmeric; holy basil; ginger; green tea; Chinese goldthread; hu zhang; oregano; barberry; and Baikal skullcap…

—The Tan Sheet, 9/27/04